Core Viewpoint - Beijing Puxi Pharmaceutical Technology Co., Ltd. (Puxi Pharma) has submitted its listing application on the Hong Kong Stock Exchange, aiming for a valuation of approximately 2.4 billion RMB, despite currently having no approved products and facing significant financial losses [1][2]. Company Overview - Puxi Pharma focuses on the field of immune inflammation, positioning itself as a leader in localized delivery targeted therapies. The company was established in 2016 and has developed a core technology platform centered on innovative design and localized delivery [1][2]. - The company has not generated any product sales revenue, reporting net losses of approximately 178 million RMB and 125 million RMB for the fiscal years 2024 and the first nine months of 2025, respectively [1][2]. Product Pipeline - Puxi Pharma's core product, PG-011 (Pumexitinib), is a JAK1/JAK2 inhibitor designed for external use, with formulations including gel and nasal spray currently in late-stage clinical trials [2][3]. - The Pumexitinib gel is the first JAK inhibitor gel globally for treating atopic dermatitis, having completed Phase III trials for adults and adolescents aged 12 to 17, with plans to expand indications to children aged 2 to 11 [2][3]. - The nasal spray formulation is the first clinical-stage JAK inhibitor for treating seasonal allergic rhinitis (SAR) and is currently in Phase III trials for adults [3]. Market Potential - The global autoimmune disease drug market is projected to grow from $116.9 billion in 2019 to $143.1 billion by 2024, with a compound annual growth rate (CAGR) of 4.1%. The market is expected to reach $179.5 billion and $217 billion by 2028 and 2033, respectively [4][5]. - In China, the autoimmune disease drug market is anticipated to expand from 16.2 billion RMB in 2019 to 32.8 billion RMB by 2024, with a CAGR of 15.1% [5]. Competitive Landscape - The JAK inhibitor market is highly competitive, with three oral JAK1 inhibitors already approved in China for treating moderate to severe atopic dermatitis, alongside 19 other candidates in clinical stages [5][6]. - Puxi Pharma faces challenges as a latecomer in a crowded market, needing to establish differentiation in efficacy, safety, or compliance to succeed [5][6]. Commercialization Strategy - Puxi Pharma has signed an exclusive commercialization agreement with a subsidiary of Jichuan Pharmaceutical, granting them rights to commercialize the Pumexitinib nasal spray in China, with a potential payment of up to 100 million RMB [7]. - The company’s reliance on the core product for valuation and cash flow is significant, as other pipeline candidates are still in early development stages [7].

Core Viewpoint - Beijing Puxi Pharmaceutical Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, aiming to raise funds due to its urgent financial situation and lack of product revenue [1][2]. Company Overview - Puxi Pharmaceutical focuses on the field of immune inflammation, positioning itself as a leader in localized delivery targeted therapies [1]. - The company was established in 2016 and has developed a core technology platform centered on innovative design and localized delivery [1]. - As of September 2025, the company reported cash and cash equivalents of only 155 million RMB, highlighting its urgent need for financing through the IPO [1]. Product Pipeline - The core product, PG-011 (Pumexitinib), is a JAK1/JAK2 inhibitor designed for external use, with formulations in gel and nasal spray currently in late-stage clinical trials [2][3]. - Pumexitinib gel is the first JAK inhibitor gel globally for treating atopic dermatitis, having completed Phase III trials for adults and adolescents aged 12 to 17 [2]. - The nasal spray formulation is the first clinical-stage JAK inhibitor for treating seasonal allergic rhinitis, currently in Phase III trials for adults [3]. Market Potential - The global autoimmune disease drug market is projected to grow from $116.9 billion in 2019 to $143.1 billion by 2024, with a compound annual growth rate (CAGR) of 4.1% [4]. - The Chinese autoimmune disease drug market is expected to expand from 16.2 billion RMB in 2019 to 32.8 billion RMB by 2024, with a much higher CAGR of 15.1% [6]. Competitive Landscape - The JAK inhibitor market is highly competitive, with multiple oral JAK1 inhibitors already approved in China for treating moderate to severe atopic dermatitis [8]. - Puxi Pharmaceutical faces significant challenges as a latecomer in a crowded market, needing to establish differentiation in efficacy, safety, or compliance [8]. Commercialization Strategy - The company has signed an exclusive commercialization agreement with Jichuan Pharmaceutical for Pumexitinib nasal spray in China, receiving up to 100 million RMB in payment [12]. - The success of Puxi Pharmaceutical's products will heavily depend on the approval timelines and outcomes of negotiations with health insurance for pricing [10][12].

Group 1 - The core viewpoint of the article is that Beijing Puxi Pharmaceutical Technology Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, aiming to become a leader in targeted therapy for immune inflammation [1] - The company was established in 2016 and focuses on innovative design and precise local delivery in the treatment of chronic inflammatory diseases, providing effective, safe, and long-term patient satisfaction solutions [1] Group 2 - Puxi Pharmaceutical has developed its core product PG-011 (Pumeixinine), which comes in two formulations: a gel for atopic dermatitis and a nasal spray for allergic rhinitis [3] - The company also has a diversified pipeline of candidate products, including PG-033 tablets for pruritus, PG-018 tablets for autoimmune kidney disease, and PG-040 eye drops for glaucoma [3]

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 PrimeGenX Therapeutics Co., Ltd. 北京普祺醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警 告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資訊並不完整，亦可能會作出重大變動。您閱覽本文件，即代表您知悉、 接納並向北京普祺醫藥科技股份有限公司（「本公司」）、其聯席保薦人、整體協調人、顧問或包銷團成員 表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，準投資者務請僅依據呈交香港公司註冊處註冊的本公司招 股章程作出投資決定；有關文本將於發售期內向公眾人士刊發。 (i) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的；投資者不應根據本文件中 的資料作出任何投資決定； (ii) 在聯交所網站登載本文件 ...